Search Details

Word: compounded (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...physicians have long used to treat it, including that old standby streptomycin. New drugs, with different mechanisms of action, would be a great help, particularly if they shortened the present six months' time required for treatment. The linezolid family, for example, appears to hold some promise, as does a compound the Seattle-based PathoGenesis Corp. is investigating...

Author: /time Magazine | Title: The Antibiotics Crisis | 1/15/2001 | See Source »

...past few months, it's become nearly impossible to buy Ketaset in New York City's underground drug market. Made by Fort Dodge, an Iowa-based pharmaceutical firm, Ketaset is a brand of ketamine, a compound that blocks certain neuroreceptors, causing hallucinations in high doses and, in lower doses, a fuzzy dissociation--like the warmth of a couple of Jim Beams. Legally, it's used as an anesthetic. Illegally, one snorts ketamine because the fuzziness lasts half an hour and doesn't produce bourbon's four-Advil hangover...

Author: /time Magazine | Title: Recreational Pharmaceuticals | 1/15/2001 | See Source »

...Dani Bolognesi still remembers the afternoon in 1994 when one of his research colleagues, Tom Matthews, ran into his office at Duke University with some exciting news. While searching for something that might work as a vaccine against HIV, Matthews had stumbled upon a compound that blocked the AIDS virus from binding to--and thus infecting--healthy cells. "I remember it as if it were yesterday," says Bolognesi, now CEO of the company he co-founded to explore the compound's commercial potential. "He said, 'You're not going to believe this. I've got something that's blocking fusion...

Author: /time Magazine | Title: The Hunt For Cures: AIDS | 1/15/2001 | See Source »

...turns out that the compound Matthews identified doesn't work as an AIDS vaccine, but it may still make a very good AIDS drug. It belongs to a family of molecules known as entry inhibitors that, as the name suggests, prevent HIV's entry into healthy immune cells. While none are yet available in pharmacies, they are probably the most promising new class of anti-HIV drugs under review. Bolognesi's company, Trimeris, based in Durham, N.C., collaborates with Hoffman-LaRoche and is already in the final stages of human testing with one compound and in the earliest phases...

Author: /time Magazine | Title: The Hunt For Cures: AIDS | 1/15/2001 | See Source »

Trimeris' compound, called T-20, blocks the final structural contortion from taking place. For this reason it and a second candidate, T-1249, are known as fusion inhibitors. Progenics has been testing a different type of entry inhibitor, a molecular decoy for CD4 whose job is to find, bind and lure HIV away from the real CD4 cells...

Author: /time Magazine | Title: The Hunt For Cures: AIDS | 1/15/2001 | See Source »

Previous | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | Next